Kisspeptin-10 FAQ: common questions answered
A short-acting experimental peptide that triggers reproductive hormone release.
Also called: KP-10, KP10, Kisspeptin 112-121, Metastin 45-54, NSC 741805.
Reproductive axis peptides · KISS1 receptor agonist.
- Is Kisspeptin-10 FDA-approved? No. PCAC voted 0 yes, 11 no on October 29, 2024. This was advisory, not an approval or final rule. No FDA-approved KP-10 label was found.
- How do people take it? Under the skin, once daily. Source: reported by users, not an established dose.
- What's the difference between Kisspeptin-10 and Gonadorelin? Kisspeptin-10: a short-acting experimental peptide that triggers reproductive hormone release. Gonadorelin: a short-acting fertility hormone used in tests and specialist pump therapy. Why people pair them: reported with KP-10 during TRT to support reproductive signaling. The home combination is untested.
- Can I take it with Gonadorelin? Reported with KP-10 during TRT to support reproductive signaling. The home combination is untested. Duplicate stimulation of the same axis; no established combined dose. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). The S2.2.1 restriction applies to male athletes. The ingredient, formulation and athlete-specific therapeutic use exemption must be checked with the antidoping authority.
- How long does a mixed vial last? Community reports use refrigeration. No validated home-use expiry or sterility period was found; a clear vial is not proof of sterility.
Related to Kisspeptin-10
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
- Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks, Health Canada
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men., Yeung AC et al. · European journal of endocrinology · 2026
- Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men., Naveed A et al. · Hormones (Athens, Greece) · 2026
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans., Galbiati F et al. · Journal of neuroendocrinology · 2026
- Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans., Mills EG et al. · EBioMedicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.